NCT00002168

Brief Summary

The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P50-P75 for not_applicable hiv-infections

Geographic Reach
2 countries

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

October 2, 2007

Status Verified

October 1, 2007

First QC Date

November 2, 1999

Last Update Submit

October 1, 2007

Conditions

Keywords

DidanosineDrug Therapy, CombinationZidovudineStavudineHIV Protease InhibitorsCD4 Lymphocyte CountLamivudineIndinavirReverse Transcriptase InhibitorsAnti-HIV AgentsViral Load

Interventions

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must have:
  • Documented HIV infection.
  • CD4 cell count of 200 - 700 cells/mm3.

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • AIDS defining condition within 1 month of study entry.
  • Prior Medication:
  • Excluded:
  • Patients with any history of antiretroviral therapy treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

East Bay AIDS Clinic

Berkeley, California, 94705, United States

Location

Harbor UCLA Med Ctr / Division of Immunology / N-24

Torrance, California, 90509, United States

Location

Anderson Clinical Research

Washington D.C., District of Columbia, 20037, United States

Location

George Washington Med Ctr / Clinical Trials Unit

Washington D.C., District of Columbia, 20037, United States

Location

Chicago Ctr for Clinical Research

Chicago, Illinois, 60610, United States

Location

Northwestern Univ

Chicago, Illinois, 60611, United States

Location

Univ of Nebraska

Omaha, Nebraska, 68195, United States

Location

Univ of North Carolina / Infectious Disease Division

Chapel Hill, North Carolina, 27599, United States

Location

The Nalle Clinic / Clinical Research Dept

Charlotte, North Carolina, 28207, United States

Location

Univ of Pennsylvania / Infectious Diseases Division

Philadelphia, Pennsylvania, 19104, United States

Location

Southwest Infectious Disease Association / PA

Dallas, Texas, 75225, United States

Location

Univ of Texas Southwestern Med Ctr of Dallas

Dallas, Texas, 75235, United States

Location

Hosp Regional de Ponce - Area Vieja

Ponce, 00731, Puerto Rico

Location

MeSH Terms

Conditions

HIV Infections

Interventions

IndinavirLamivudineStavudineZidovudineDidanosine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

PyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsZalcitabineDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and NucleosidesDideoxynucleosidesThymidineInosinePurine NucleosidesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingRibonucleosides

Study Design

Study Type
interventional
Phase
not applicable
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

October 2, 2007

Record last verified: 2007-10

Locations